StockTipsArenaBeta

BUY Krishna Institute of Medical Sciences Limited — ICICI Securities

BUYKrishna Institute of Medical Sciences Limited

byICICI SecuritiesHorizon: NA (inferred 1 year)9 Sept 2025via Institutional / Brokerage Research

Entry₹748.15Inferred
Target₹875
Total upside +16.96%
Stop lossNot given
CMP₹764.5515h ago
Active+2.19%+14.45%upside left 1d left
Follow ICICI Securities for new calls(68% target hit, 1025 closed calls)Get alertsWatch KIMS for new buy/sell callsGet alertsSee 1 other Long-term call on KIMSSee 47 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 8:02 am IST
9 supporting12 neutral1 opposing
Supports the BUY call (9)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·7 Sept · yesterday

This hospital stock could hit ₹1,000 over the next 12 months, Investec predicts with a 'buy' rating

NewsCnbc-Tv18·3 Sept · 4d ago

(opens in new tab)

Entered into Operations and Management Agreement and Call Option Agreement with Aurevia Hospitals Private Limited.

NSE · Agreements·20 Aug · 3w ago

(opens in new tab)

KIMS entered into Operations and Management agreement with Aurevia Hospitals Private Limited.

BSE · Company Update·20 Aug · 3w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·19 Aug · 3w ago

Neutral / worth noting (12)

Indian Hospital Chains Expand Capacity Despite Staffing Crunch

NewsGoogle News·27 Aug · 2w ago

(opens in new tab)

KIMS to operate 250-bed Arete Hospital in Hyderabad under 5-year O&M deal

NewsCnbc-Tv18·20 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.